Corline Biomedical AB (STO:CLBIO)
Sweden · Delayed Price · Currency is SEK 14.25
+0.05 (0.35%)
Sep 22, 2026, 1:48 PM CET
Corline Biomedical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12.39 | 7.65 | 9.78 | 35.52 | 23.55 | 7.06 | |
Revenue Growth | 54.37% | -21.73% | -72.48% | 50.82% | 233.48% | 91.07% |
Cost of Revenue | 1.41 | 2.36 | 3.83 | 7.14 | 9.87 | 8.09 |
Gross Profit | 10.98 | 5.29 | 5.94 | 28.38 | 13.69 | -1.03 |
Selling, General & Admin | 23.34 | 20.35 | 26.93 | 28.74 | 20.89 | 15.95 |
Other Operating Expenses | -0.03 | -0.36 | -7.5 | 1.74 | -9.59 | -10.1 |
Operating Expenses | 23.4 | 20.08 | 19.53 | 30.58 | 11.36 | 5.88 |
Operating Income | -12.42 | -14.79 | -13.59 | -2.2 | 2.33 | -6.91 |
Interest Expense | -0.01 | -0 | -0.03 | -0.03 | - | -0.01 |
Interest & Investment Income | 0.04 | 0.04 | 0 | 0.01 | - | - |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.41 | 0.41 | - | - |
Other Non Operating Income (Expenses) | 0.03 | - | - | - | - | - |
EBT Excluding Unusual Items | -12.32 | -14.71 | -13.2 | -1.81 | 2.33 | -6.92 |
Asset Writedown | - | - | -9.99 | - | - | - |
Pretax Income | -12.32 | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 |
Net Income | -12.32 | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 |
Net Income to Common | -12.32 | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 25 | 25 | 22 | 21 | 21 | 20 |
Shares Outstanding (Diluted) | 25 | 25 | 22 | 21 | 22 | 20 |
Shares Change | 9.08% | 13.40% | 1.49% | -2.19% | 7.50% | 22.58% |
EPS (Basic) | -0.48 | -0.59 | -1.06 | -0.08 | 0.11 | -0.34 |
EPS (Diluted) | -0.48 | -0.59 | -1.06 | -0.08 | 0.11 | -0.34 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -14.82 | -17.74 | -8.64 | 0.75 | -6.61 | -4.98 |
Free Cash Flow Per Share | -0.58 | -0.72 | -0.40 | 0.04 | -0.30 | -0.24 |
Gross Margin | 88.63% | 69.15% | 60.81% | 79.90% | 58.11% | -14.59% |
Operating Margin | -100.24% | -193.24% | -139.01% | -6.20% | 9.89% | -97.83% |
Profit Margin | -99.48% | -192.31% | -237.28% | -5.09% | 9.89% | -98.02% |
Free Cash Flow Margin | -119.64% | -231.81% | -88.38% | 2.12% | -28.05% | -70.45% |
EBITDA | -12.31 | -14.68 | -13.49 | -2.1 | 2.39 | -6.88 |
EBITDA Margin | -99.37% | -191.88% | -138.04% | -5.92% | 10.13% | -97.39% |
D&A For EBITDA | 0.11 | 0.1 | 0.1 | 0.1 | 0.06 | 0.03 |
EBIT | -12.42 | -14.79 | -13.59 | -2.2 | 2.33 | -6.91 |
EBIT Margin | -100.24% | -193.24% | -139.01% | -6.20% | 9.89% | -97.83% |
Revenue as Reported | 12.82 | 8.62 | 17.69 | 35.93 | 33.33 | 17.26 |